Biotech Values

[mcbio]

Could be. I read it that way at first. But it is possible that they are just saving it for a conference.

I just listened to their 10/9/12 presentation at BIO Investor Forum and there is reference to if Alpha 1 HDL is 1 mg/deciliter more in one person compared to another, that person has a 26% lower chance of cardiovascular risk. In the last trial (the one we are discussing), RVX-208 increased Alpha 1 HDL by 3 mg/deciliter on average across the trial. The CEO also said that full details will be published with Dr. Nissen in the future. So, sounds like they are just holding the full details for a conference.

Speaking of Dr. Nissen, do you find it encouraging that he's involved with the Resverlogix studies?

I would imagine if Resverlogix can show meaningful plaque reduction in the ongoing Phase 2 ASSURE trial around mid-2013, there's presumably meaningful upside potential from current ~$150M market cap. Would you agree? I think the question is how much confidence one has around that data being positive. Seems hard to predict. If it does work, they have a strong patent life as it was noted at BIO that RVX-208 has patent life out to 2031.